Friday 5/30 Insider Buying Report: GBDC, CORZ

Lawrence E. Golub, Chairman of Golub Capital BDC (GBDC), recently purchased 6,059,971 shares at $15.13 each, totaling $91.69M, marking his tenth purchase of GBDC in the past year. Separately, Yadin Rozov bought $1.2M worth of Core Scientific (CORZ) at $10.87 per share; however, CORZ is currently trading lower than Rozov's purchase price, presenting a potential opportunity for investors.

Analysis

Insider buying activity, generally viewed as a positive signal as insiders presumably purchase shares expecting future appreciation, has been observed in two notable instances. At Golub Capital BDC (GBDC), Chairman Lawrence E. Golub made a significant investment of $91.69 million, acquiring 6,059,971 shares at $15.13 each. This is Golub's tenth purchase in the past year, during which he previously invested a total of $12.69 million at an average price of $15.62 per share, underscoring persistent insider conviction and aligning with a positive per-ticker sentiment score of 0.7 for GBDC. The stock saw a brief uptick to $15.24 post-purchase, realizing a momentary 0.7% gain for Golub, before trading down about 0.5% on Friday. Conversely, at Core Scientific (CORZ), Yadin Rozov purchased $1.2 million worth of shares at $10.87 each. Despite this insider buy, CORZ traded down about 1.8% on Friday, with its price reaching as low as $10.46, which is 3.8% below Rozov's purchase price, and this performance is consistent with a negative per-ticker sentiment of -0.2 for the stock. This divergence for CORZ presents a scenario where external investors could potentially acquire shares at a more favorable price than the insider, though the negative sentiment warrants consideration.

Key Decisions for Investors

• The substantial and repeated insider buying by Golub Capital BDC's Chairman, totaling over $100 million in the last year including the recent transaction, coupled with positive ticker sentiment, suggests investors might view GBDC as having strong insider confidence, warranting further due diligence on its fundamentals.
• For Core Scientific, while an insider purchase typically signals confidence, the subsequent price decline below the insider's entry point may present a tactical opportunity for bargain hunters, but this should be carefully weighed against the stock's recent negative price movement and associated negative sentiment.
• Investors should consider these insider transactions as one component of a comprehensive investment thesis, integrating them with broader market analysis and company-specific financial health assessments before making capital allocation decisions.